In someone with an allergy, the immune system overreacts, producing IgE that travels to cells to release ... produces IgE antibodies. “We’ve discovered a type of memory B cell that had unique ...

First-in-human data for the trispecific antibody “suggest a paradigm shift” for the relapsed/refractory multiple myeloma ...

B lymphocytes exhibit dual roles in tumorigenesis, acting as both allies and adversaries in the tumor microenvironment (TME).

The antibody, called IPH6501, is now being evaluated in patients with relapsed or unresponsive B ... T cells. T-cell engagers, however, can cause serious toxicities, according to the release ...

Researchers at Friedrich-Alexander-Universität Erlangen-Nürnberg have identified a previously undocumented, organ-specific ...

A patient with relapsed follicular lymphoma achieved complete remission one month after PMB-CT01 treatment in the phase 1 PMB ...

Sanofi completes acquisition of DR-0201 Paris, May 27, 2025. Sanofi announces the completion of its acquisition of DR-0201, a targeted bispecific myeloid cell engager, from Dren Bio, Inc., a private ...

B cell biohack: Immune cells to churn out custom antibodies. ScienceDaily . Retrieved May 27, 2025 from www.sciencedaily.com / releases / 2024 / 07 / 240722155148.htm ...

Approval based on Phase III STARGLO study where Columvi in combination with chemotherapy showed a 41% reduction in the risk of death compared to MabThera/Rituxan plus chemotherapy1,2 DLBCL is an ...